5tkk - Revision history

OCA at 15:41, 6 March 2024

OCA — Wed, 06 Mar 2024 15:41:37 GMT

←Older revision		Revision as of 15:41, 6 March 2024
Line 3:		Line 3:
	<StructureSection load='5tkk' size='340' side='right'caption='[[5tkk]], [[Resolution\|resolution]] 1.55Å' scene=''>		<StructureSection load='5tkk' size='340' side='right'caption='[[5tkk]], [[Resolution\|resolution]] 1.55Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5tkk]] is a 3 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Lk3_transgenic_mice Lk3 transgenic mice~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5TKK OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://proteopedia.org/fgij/fg.htm?mol=5TKK FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5tkk]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1] and [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5TKK OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5TKK FirstGlance]. <br>
-	</td></tr><tr id='~~related~~'><td class="sblockLbl"><b>[[~~Related_structure~~\|~~Related~~:]]</b></td><td class="sblockDat">[[~~5tkj~~\|~~5tkj~~]]</td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.55Å</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://proteopedia.org/fgij/fg.htm?mol=5tkk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5tkk OCA], [~~http~~://pdbe.org/5tkk PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=5tkk RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/5tkk PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=5tkk ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5tkk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5tkk OCA], [https://pdbe.org/5tkk PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5tkk RCSB], [https://www.ebi.ac.uk/pdbsum/5tkk PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5tkk ProSAT]</span></td></tr>
	</table>		</table>
-	~~<div style~~=~~"background-color:#fffaf0;">~~	+	== Function ==
-	=~~= Publication Abstract from PubMed~~ ==	+	[https://www.uniprot.org/uniprot/ENV_HV1H2 ENV_HV1H2] The surface protein gp120 (SU) attaches the virus to the host lymphoid cell by binding to the primary receptor CD4. This interaction induces a structural rearrangement creating a high affinity binding site for a chemokine coreceptor like CXCR4 and/or CCR5. This peculiar 2 stage receptor-interaction strategy allows gp120 to maintain the highly conserved coreceptor-binding site in a cryptic conformation, protected from neutralizing antibodies. Since CD4 also displays a binding site for the disulfide-isomerase P4HB/PDI, a P4HB/PDI-CD4-CXCR4-gp120 complex may form. In that complex, P4HB/PDI could reach and reduce gp120 disulfide bonds, causing major conformational changes in gp120. TXN, another PDI family member could also be involved in disulfide rearrangements in Env during fusion. These changes are transmitted to the transmembrane protein gp41 and are thought to activate its fusogenic potential by unmasking its fusion peptide.<ref>PMID:19410541</ref> Surface protein gp120 (SU) may target the virus to gut-associated lymphoid tissue (GALT) by binding host ITGA4/ITGB7 (alpha-4/beta-7 integrins), a complex that mediates T-cell migration to the GALT. Interaction between gp120 and ITGA4/ITGB7 would allow the virus to enter GALT early in the infection, infecting and killing most of GALT's resting CD4+ T-cells. This T-cell depletion is believed to be the major insult to the host immune system leading to AIDS (By similarity).<ref>PMID:19410541</ref> The surface protein gp120 is a ligand for CD209/DC-SIGN and CLEC4M/DC-SIGNR, which are respectively found on dendritic cells (DCs), and on endothelial cells of liver sinusoids and lymph node sinuses. These interactions allow capture of viral particles at mucosal surfaces by these cells and subsequent transmission to permissive cells. DCs are professional antigen presenting cells, critical for host immunity by inducing specific immune responses against a broad variety of pathogens. They act as sentinels in various tissues where they take up antigen, process it, and present it to T-cells following migration to lymphoid organs. HIV subverts the migration properties of dendritic cells to gain access to CD4+ T-cells in lymph nodes. Virus transmission to permissive T-cells occurs either in trans (without DCs infection, through viral capture and transmission), or in cis (following DCs productive infection, through the usual CD4-gp120 interaction), thereby inducing a robust infection. In trans infection, bound virions remain infectious over days and it is proposed that they are not degraded, but protected in non-lysosomal acidic organelles within the DCs close to the cell membrane thus contributing to the viral infectious potential during DCs' migration from the periphery to the lymphoid tissues. On arrival at lymphoid tissues, intact virions recycle back to DCs' cell surface allowing virus transmission to CD4+ T-cells. Virion capture also seems to lead to MHC-II-restricted viral antigen presentation, and probably to the activation of HIV-specific CD4+ cells.<ref>PMID:19410541</ref> The transmembrane protein gp41 (TM) acts as a class I viral fusion protein. Under the current model, the protein has at least 3 conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of viral and target intracellular membranes, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes. Complete fusion occurs in host cell endosomes and is dynamin-dependent, however some lipid transfer might occur at the plasma membrane. The virus undergoes clathrin-dependent internalization long before endosomal fusion, thus minimizing the surface exposure of conserved viral epitopes during fusion and reducing the efficacy of inhibitors targeting these epitopes. Membranes fusion leads to delivery of the nucleocapsid into the cytoplasm.<ref>PMID:19410541</ref> The envelope glyprotein gp160 precursor down-modulates cell surface CD4 antigen by interacting with it in the endoplasmic reticulum and blocking its transport to the cell surface (By similarity).<ref>PMID:19410541</ref> The gp120-gp41 heterodimer seems to contribute to T-cell depletion during HIV-1 infection. The envelope glycoproteins expressed on the surface of infected cells induce apoptosis through an interaction with uninfected cells expressing the receptor (CD4) and the coreceptors CXCR4 or CCR5. This type of bystander killing may be obtained by at least three distinct mechanisms. First, the interaction between the 2 cells can induce cellular fusion followed by nuclear fusion within the syncytium. Syncytia are condemned to die from apoptosis. Second, the 2 interacting cells may not fuse entirely and simply exchange plasma membrane lipids, after a sort of hemifusion process, followed by rapid death. Third, it is possible that virus-infected cells, on the point of undergoing apoptosis, fuse with CD4-expressing cells, in which case apoptosis is rapidly transmitted from one cell to the other and thus occurs in a sort of contagious fashion.<ref>PMID:19410541</ref> The gp120-gp41 heterodimer allows rapid transcytosis of the virus through CD4 negative cells such as simple epithelial monolayers of the intestinal, rectal and endocervical epithelial barriers. Both gp120 and gp41 specifically recognize glycosphingolipids galactosyl-ceramide (GalCer) or 3' sulfo-galactosyl-ceramide (GalS) present in the lipid rafts structures of epithelial cells. Binding to these alternative receptors allows the rapid transcytosis of the virus through the epithelial cells. This transcytotic vesicle-mediated transport of virions from the apical side to the basolateral side of the epithelial cells does not involve infection of the cells themselves.<ref>PMID:19410541</ref>
-	~~A central goal of HIV~~-~~1 vaccine research is~~ the ~~elicitation of antibodies capable of~~ neutralizing ~~diverse primary isolates of HIV~~-1. ~~Here we show~~ that ~~focusing the immune response~~ to ~~exposed N-terminal residues of~~ the fusion peptide, a ~~critical component of~~ the ~~viral entry machinery~~ and the ~~epitope~~ of ~~antibodies elicited~~ by HIV-1 infection, through ~~immunization with fusion peptide-coupled carriers~~ and ~~prefusion stabilized envelope trimers~~, ~~induces cross~~-~~clade neutralizing responses~~. In ~~mice~~, ~~these immunogens elicited monoclonal antibodies capable of neutralizing up~~ to ~~31% of a cross~~-~~clade panel~~ of ~~208~~ HIV-~~1 strains~~. ~~Crystal and cryoelectron microscopy structures of these antibodies revealed fusion peptide conformational diversity~~ as a ~~molecular explanation for~~ the ~~cross~~-~~clade neutralization~~. ~~Immunization~~ of ~~guinea pigs~~ and ~~rhesus macaques induced similarly broad~~ fusion peptide-~~directed neutralizing responses, suggesting translatability~~. The ~~N terminus~~ of the ~~HIV~~-1 fusion ~~peptide is~~ thus ~~a promising target~~ of ~~vaccine efforts aimed at eliciting broadly neutralizing antibodies~~.	+
-		+
-	~~Epitope-based vaccine design yields~~ fusion ~~peptide-directed antibodies that neutralize diverse strains~~ of HIV-1.,~~Xu K~~, ~~Acharya P~~, ~~Kong R~~, ~~Cheng C~~, ~~Chuang GY, Liu K~~, ~~Louder MK, O'Dell S, Rawi R, Sastry M, Shen CH, Zhang B, Zhou T, Asokan M, Bailer RT, Chambers M~~, ~~Chen X, Choi CW, Dandey VP, Doria~~-Rose NA, Druz A, Eng ET, Farney SK, Foulds KE, Geng H, Georgiev IS, Gorman J, Hill KR, Jafari AJ, Kwon YD, Lai YT, Lemmin T, McKee K, Ohr TY, Ou L, Peng D, Rowshan AP, Sheng Z, Todd JP, Tsybovsky Y, Viox EG, Wang Y, Wei H, Yang Y, Zhou AF, ~~Chen R, Yang L, Scorpio DG, McDermott AB, Shapiro L, Carragher B, Potter CS, Mascola JR, Kwong PD Nat Med~~. ~~2018 Jun;24(6):857-867. doi: 10.1038/s41591-018-0042-6. Epub 2018 Jun 4. PMID:29867235~~<ref>PMID:~~29867235~~</ref>	+
-		+
-	~~From MEDLINE®/PubMed®, a database~~ of the U.S. ~~National Library~~ of ~~Medicine~~.<br>	+
-	~~</div>~~	+
-	~~<div class="pdbe-citations 5tkk" style="background-color~~:~~#fffaf0;">~~</~~div~~>	+
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human immunodeficiency virus 1]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: ~~Lk3 transgenic mice~~]]	+	[[Category: Mus musculus]]
-	[[Category: Kwong~~, P D~~]]	+	[[Category: Kwong PD]]
-	[[Category: Liu, K]]	+	[[Category: Liu K]]
-	[[Category: Xu, K]]	+	[[Category: Xu K]]
-	~~[[Category: Antibody]]~~	+
-	~~[[Category: Complex]]~~	+
-	~~[[Category: Fusion-peptide]]~~	+
-	~~[[Category: Immune system]]~~	+
-	~~[[Category: Mouse]]~~	+
-	~~[[Category: Neutralizing~~]]	+

OCA at 12:12, 23 September 2020

OCA — Wed, 23 Sep 2020 12:12:35 GMT

←Older revision		Revision as of 12:12, 23 September 2020
Line 1:		Line 1:

	==Structure of mouse vaccination-elicited HIV neutralizing antibody vFP5.01 in complex with HIV-1 fusion peptide residue 512-519==		==Structure of mouse vaccination-elicited HIV neutralizing antibody vFP5.01 in complex with HIV-1 fusion peptide residue 512-519==
-	<StructureSection load='5tkk' size='340' side='right' caption='[[5tkk]], [[Resolution\|resolution]] 1.55Å' scene=''>	+	<StructureSection load='5tkk' size='340' side='right'caption='[[5tkk]], [[Resolution\|resolution]] 1.55Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5tkk]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5TKK OCA]. For a <b>guided tour on the structure components</b> use [http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5TKK FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5tkk]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5TKK OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=5TKK FirstGlance]. <br>
	</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5tkj\|5tkj]]</td></tr>		</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5tkj\|5tkj]]</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5tkk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5tkk OCA], [http://pdbe.org/5tkk PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5tkk RCSB], [http://www.ebi.ac.uk/pdbsum/5tkk PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5tkk ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=5tkk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5tkk OCA], [http://pdbe.org/5tkk PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5tkk RCSB], [http://www.ebi.ac.uk/pdbsum/5tkk PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5tkk ProSAT]</span></td></tr>
	</table>		</table>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
Line 20:		Line 20:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Large Structures]]
	[[Category: Lk3 transgenic mice]]		[[Category: Lk3 transgenic mice]]
	[[Category: Kwong, P D]]		[[Category: Kwong, P D]]

OCA at 05:50, 27 June 2018

OCA — Wed, 27 Jun 2018 05:50:22 GMT

←Older revision		Revision as of 05:50, 27 June 2018
Line 3:		Line 3:
	<StructureSection load='5tkk' size='340' side='right' caption='[[5tkk]], [[Resolution\|resolution]] 1.55Å' scene=''>		<StructureSection load='5tkk' size='340' side='right' caption='[[5tkk]], [[Resolution\|resolution]] 1.55Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5tkk]] is a 3 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5TKK OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5TKK FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5tkk]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5TKK OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5TKK FirstGlance]. <br>
	</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5tkj\|5tkj]]</td></tr>		</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5tkj\|5tkj]]</td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5tkk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5tkk OCA], [http://pdbe.org/5tkk PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5tkk RCSB], [http://www.ebi.ac.uk/pdbsum/5tkk PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5tkk ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5tkk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5tkk OCA], [http://pdbe.org/5tkk PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5tkk RCSB], [http://www.ebi.ac.uk/pdbsum/5tkk PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5tkk ProSAT]</span></td></tr>
	</table>		</table>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	A central goal of HIV-1 vaccine research is the elicitation of antibodies capable of neutralizing diverse primary isolates of HIV-1. Here we show that focusing the immune response to exposed N-terminal residues of the fusion peptide, a critical component of the viral entry machinery and the epitope of antibodies elicited by HIV-1 infection, through immunization with fusion peptide-coupled carriers and prefusion stabilized envelope trimers, induces cross-clade neutralizing responses. In mice, these immunogens elicited monoclonal antibodies capable of neutralizing up to 31% of a cross-clade panel of 208 HIV-1 strains. Crystal and cryoelectron microscopy structures of these antibodies revealed fusion peptide conformational diversity as a molecular explanation for the cross-clade neutralization. Immunization of guinea pigs and rhesus macaques induced similarly broad fusion peptide-directed neutralizing responses, suggesting translatability. The N terminus of the HIV-1 fusion peptide is thus a promising target of vaccine efforts aimed at eliciting broadly neutralizing antibodies.
		+
		+	Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.,Xu K, Acharya P, Kong R, Cheng C, Chuang GY, Liu K, Louder MK, O'Dell S, Rawi R, Sastry M, Shen CH, Zhang B, Zhou T, Asokan M, Bailer RT, Chambers M, Chen X, Choi CW, Dandey VP, Doria-Rose NA, Druz A, Eng ET, Farney SK, Foulds KE, Geng H, Georgiev IS, Gorman J, Hill KR, Jafari AJ, Kwon YD, Lai YT, Lemmin T, McKee K, Ohr TY, Ou L, Peng D, Rowshan AP, Sheng Z, Todd JP, Tsybovsky Y, Viox EG, Wang Y, Wei H, Yang Y, Zhou AF, Chen R, Yang L, Scorpio DG, McDermott AB, Shapiro L, Carragher B, Potter CS, Mascola JR, Kwong PD Nat Med. 2018 Jun;24(6):857-867. doi: 10.1038/s41591-018-0042-6. Epub 2018 Jun 4. PMID:29867235<ref>PMID:29867235</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 5tkk" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Lk3 transgenic mice]]
	[[Category: Kwong, P D]]		[[Category: Kwong, P D]]
	[[Category: Liu, K]]		[[Category: Liu, K]]

OCA at 05:52, 4 April 2018

OCA — Wed, 04 Apr 2018 05:52:53 GMT

←Older revision		Revision as of 05:52, 4 April 2018
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 5tkk is ~~ON HOLD until Apr 04 2019~~	+	==Structure of mouse vaccination-elicited HIV neutralizing antibody vFP5.01 in complex with HIV-1 fusion peptide residue 512-519==
-		+	<StructureSection load='5tkk' size='340' side='right' caption='[[5tkk]], [[Resolution\|resolution]] 1.55Å' scene=''>
-	~~Authors~~:	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[5tkk]] is a 3 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5TKK OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5TKK FirstGlance]. <br>
-	~~Description~~:	+	</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5tkj\|5tkj]]</td></tr>
-	[[Category: ~~Unreleased Structures~~]]	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5tkk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5tkk OCA], [http://pdbe.org/5tkk PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5tkk RCSB], [http://www.ebi.ac.uk/pdbsum/5tkk PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5tkk ProSAT]</span></td></tr>
		+	</table>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Kwong, P D]]
		+	[[Category: Liu, K]]
		+	[[Category: Xu, K]]
		+	[[Category: Antibody]]
		+	[[Category: Complex]]
		+	[[Category: Fusion-peptide]]
		+	[[Category: Immune system]]
		+	[[Category: Mouse]]
		+	[[Category: Neutralizing]]

OCA at 06:59, 10 January 2018

OCA — Wed, 10 Jan 2018 06:59:13 GMT

←Older revision		Revision as of 06:59, 10 January 2018
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 5tkk is ON HOLD until ~~Paper Publication~~	+	The entry 5tkk is ON HOLD until Apr 04 2019

	Authors:		Authors:

OCA at 05:31, 25 October 2017

OCA — Wed, 25 Oct 2017 05:31:03 GMT

←Older revision		Revision as of 05:31, 25 October 2017
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 5tkk is ON HOLD	+	The entry 5tkk is ON HOLD until Paper Publication

	Authors:		Authors:

OCA: Protected "5tkk" [edit=sysop:move=sysop]

OCA — Wed, 19 Oct 2016 15:58:08 GMT

Protected "5tkk" [edit=sysop:move=sysop]

←Older revision

Revision as of 15:58, 19 October 2016

OCA: New page: '''Unreleased structure''' The entry 5tkk is ON HOLD Authors: Description: Category: Unreleased Structures

OCA — Wed, 19 Oct 2016 15:58:07 GMT

New page: '''Unreleased structure''' The entry 5tkk is ON HOLD Authors: Description: Category: Unreleased Structures

New page

'''Unreleased structure'''

The entry 5tkk is ON HOLD

Authors:

Description:
[[Category: Unreleased Structures]]